Fulgent Genetics (FLGT)
(Real Time Quote from BATS)
$20.26 USD
+0.23 (1.15%)
Updated Apr 26, 2024 12:23 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Income Statements
Fiscal Year end for Fulgent Genetics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 289 | 619 | 993 | 422 | 33 |
Cost Of Goods | 185 | 252 | 216 | 90 | 14 |
Gross Profit | 104 | 367 | 777 | 332 | 18 |
Selling & Adminstrative & Depr. & Amort Expenses | 300 | 188 | 101 | 42 | 19 |
Income After Depreciation & Amortization | -196 | 179 | 676 | 290 | 0 |
Non-Operating Income | 21 | 6 | 1 | 2 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -174 | 184 | 677 | 292 | 0 |
Income Taxes | 1 | 42 | 175 | 73 | 0 |
Minority Interest | -7 | -1 | -1 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 4 | -5 | -1 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -175 | 142 | 506 | 214 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -168 | 143 | 507 | 214 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -53 | 216 | 695 | 294 | 2 |
Depreciation & Amortization (Cash Flow) | 142 | 37 | 19 | 4 | 2 |
Income After Depreciation & Amortization | -196 | 179 | 676 | 290 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.78 | 30.96 | 30.98 | 24.06 | 18.71 |
Diluted EPS Before Non-Recurring Items | -1.55 | 5.04 | 16.38 | 8.85 | 0.02 |
Diluted Net EPS (GAAP) | -5.63 | 4.63 | 16.38 | 8.91 | -0.02 |
Fiscal Year end for Fulgent Genetics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 70.51 | 84.69 | 67.85 | 66.17 |
Cost Of Goods | NA | 45.28 | 44.84 | 47.28 | 47.36 |
Gross Profit | NA | 25.23 | 39.84 | 20.57 | 18.81 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 176.35 | 39.63 | 40.37 | 43.64 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -151.12 | 0.21 | -19.80 | -24.83 |
Non-Operating Income | NA | 5.93 | 6.65 | 5.10 | 3.78 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -145.20 | 6.86 | -14.70 | -21.05 |
Income Taxes | NA | -10.86 | 20.33 | -3.11 | -5.20 |
Minority Interest | NA | -6.19 | -0.36 | -0.36 | -0.51 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -134.33 | -13.47 | -11.59 | -15.85 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -128.15 | -13.11 | -11.23 | -15.34 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 29.77 | 30.01 | 29.81 | 29.54 |
Diluted EPS Before Non-Recurring Items | NA | -0.02 | -0.43 | -0.33 | -0.47 |
Diluted Net EPS (GAAP) | NA | -4.29 | -0.44 | -0.38 | -0.52 |